User profiles for Jafna Cox

Jafna Cox

Professor of Cardiology and of Community Health and Epidemiology, Dalhousie University …
Verified email at dal.ca
Cited by 14977

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a …

CP Cannon, A Battler, RG Brindis, JL Cox… - Journal of the American …, 2001 - jacc.org
In the field of cardiology, large-scale clinical trials and registries have provided a wealth of
data on hundreds of thousands of patients. This is especially true in the field of acute coronary …

A comprehensive view of sex-specific issues related to cardiovascular disease

…, D Rabi, J Tremblay, A Alamian, T Barnett, J Cox… - Cmaj, 2007 - Can Med Assoc
Cardiovascular disease (CVD) is the leading cause of mortality in women. In fact, CVD is
responsible for a third of all deaths of women worldwide and half of all deaths of women over …

Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries

JL Cox, DA Chiasson, AI Gotlieb - Progress in cardiovascular diseases, 1991 - Elsevier
The USE OF saphenous vein grafts (SVG) in coronary artery bypass graft (CABG) surgery is
the mainstay of the surgical treatment of ischemic heart disease. lm3 Less than 3% of …

[HTML][HTML] The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada

…, PG Norton, V Flintoft, R Blais, A Brown, J Cox… - Cmaj, 2004 - Can Med Assoc
Background: Research into adverse events (AEs) has highlighted the need to improve
patient safety. AEs are unintended injuries or complications resulting in death, disability or …

The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation

…, A Bell, JA Cairns, CC Cheung, JL Cox… - Canadian Journal of …, 2020 - Elsevier
The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines program was
developed to aid clinicians in the management of these complex patients, as well as to …

Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality

…, X Song, I Skoog, GA Broe, JL Cox… - Journal of the …, 2005 - Wiley Online Library
Objectives: To investigate the relationship between accumulated health‐related problems (deficits),
which define a frailty index in older adults, and mortality in population‐based and …

Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?

…, NJ Pearce, MJ Gardner, H Merry, JL Cox… - Journal of the American …, 2002 - jacc.org
Objectives : This study was designed to assess the prognostic significance of hyperglycemia
in acute myocardial infarction (AMI) in the thrombolytic era using contemporary criteria for …

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational studyCommentary: Varied preferences …

…, GJ Flowerdew, BF Brownell, S Nagpal, JL Cox - Bmj, 2001 - bmj.com
Objective: To determine and compare physicians' and patients' thresholds for how much
reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with …

2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation

…, D Gladstone, MS McMurtry, S Connolly, JL Cox… - Canadian Journal of …, 2014 - Elsevier
Atrial fibrillation (AF) is an extremely common clinical problem with an important population
morbidity and mortality burden. The management of AF is complex and fraught with many …

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind …

…, R Willems, C Constance, N Pranno, J Cox… - The lancet, 2022 - thelancet.com
Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation …